spartalizumab
Phase 2Monoclonal antibody
Novartisspartalizumab is a monoclonal antibody that works as a Programmed Cell Death Protein 1 Antagonist.[2] It is being investigated across 3 indications, with its most advanced program in Phase 2.[1]
spartalizumab is one of 94 small molecule programs targeting Myelodysplastic Syndromes. It is currently in Phase 2.
3
Indications
19
Total Trials
3
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
86 competitors in Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Sutent
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Fotivda
AAVEO Pharmaceuticals, Inc.
Phase 3
Zanzalintinib
Merck & Co.Phase 3
Libtayo
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Melanoma2 trials
Malignancies1 trial
Renal Cell Carcinoma1 trial
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
Active, not recruiting·—·Phase 1·NCT04028245·17 enrolled
Metastatic Colorectal Cancer1 trial
13 more indications
Nasopharyngeal Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
MET Exon 14 Skipping Mutation1 trial
Gastric Adenocarcinoma1 trial
Breast Cancer1 trial
Multiple Cancer1 trial
Myelodysplastic Syndromes1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for spartalizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]